Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Regenaflex-M Biofilm is a veterinary regenerative therapy developed by Hilltop BioSciences as a sterile bioscaffold membrane formulation for wound care in companion animals and horses. It delivers a cell-signaling cascade of cytokines, microRNA, growth factors, and exosomes to accelerate tissue healing while providing **anti-inflammatory**, **antimicrobial**, and **anti-adhesion** properties. Clinically proven to minimize scar tissue formation, prevent postoperative adhesions after abdominal or orthopedic surgery, and reduce suture leakage following intestinal anastomosis or cystotomy, it supports integration of reparative tissues and is suitable for external wounds, surgical closures, and difficult-to-heal injuries.[1][3][8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Regenaflex-M Biofilm.